Related references
Note: Only part of the references are listed.Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Francine Baumann et al.
CARCINOGENESIS (2015)
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton et al.
BRITISH JOURNAL OF CANCER (2014)
Regulatory T cells in cancer immunotherapy
Hiroyoshi Nishikawa et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Immunomodulation in cancer
Joost P. J. J. Hegmans et al.
CURRENT OPINION IN PHARMACOLOGY (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4
James Badger Wing et al.
IMMUNITY (2014)
Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?
Pietro Bovolato et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Ahmad A. Tarhini et al.
PLOS ONE (2014)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
Luana Calabro et al.
LANCET ONCOLOGY (2013)
Immunotherapy response evaluation with F-18-FDG-PET in patients with advanced stage renal cell carcinoma
Rozemarie Gilles et al.
WORLD JOURNAL OF UROLOGY (2013)
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
Christina S. Chu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
Eva Ellebaek et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
New Roads Open Up for Implementing Immunotherapy in Mesothelioma
R. Cornelissen et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma
Apostolos Nakas et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2012)
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey
P. A. Zucali et al.
LUNG CANCER (2012)
The Role of Regulatory T Cells in Mesothelioma
Demelza J. Ireland et al.
CANCER MICROENVIRONMENT (2012)
Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients
Carlos Alfaro et al.
JOURNAL OF IMMUNOLOGY (2011)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
Giovanni L. Ceresoli et al.
LUNG CANCER (2011)
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Antonella Sistigu et al.
SEMINARS IN IMMUNOPATHOLOGY (2011)
Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
Joost P. Hegmans et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
A Phase I Trial of Repeated Intrapleural Adenoviral-mediated Interferon-beta Gene Transfer for Mesothelioma and Metastatic Pleural Effusions
Daniel H. Sterman et al.
MOLECULAR THERAPY (2010)
[F-18]-Fluoro-2-deoxy-D-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model
Coralie Chaise et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Ten traps for the unwary in surgical series: A case study in mesothelioma reports
Tom Treasure et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2007)
Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses
J. P. J. J. Hegmans et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
MJ Byrne et al.
ANNALS OF ONCOLOGY (2004)
Share Paper
